Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 666-673

  Ahmann, Gregory J ^a   Wee, Joo Chng ^a   Henderson, Kimberly J ^b   Price Troska, Tammy L ^b   DeGoey, Roberta W ^b   Timm, Michael M ^b   Dispenzieri, Angela ^b   Greipp, Philip R ^b   Sable Hunt, Alicia ^c   Bergsagel, Leif ^a   Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c Multiple Myeloma Research Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD45 ANTIGEN;

ARTICLE; BONE MARROW BIOPSY; CELL COUNT; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; PLASMA CELL; PRIORITY JOURNAL; RNA ANALYSIS; RNA EXTRACTION; RNA PURIFICATION;

ANALYSIS OF VARIANCE; BONE MARROW CELLS; CELL SEPARATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOMAGNETIC SEPARATION; PLASMA CELLS; RNA; SPECIMEN HANDLING; TISSUE BANKS;

EID: 41549159202     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2649     Document Type: Article

References (12)

1. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002;99:3735-41.
2. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (y13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 2002;62:715-20.
3. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood 1996;88:2699-706.
4. Kumar S, Greipp PR, Haug J, et al. Gene expression profiling of myeloma cells at diagnosis can predict response to therapy with thalidomide and dexamethasone combination. Blood 2005;106:508.
5. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999;104:131-7.
6. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
7. Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005;105:794-803.
8. Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998;100:637-46.
9. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131-44.
10. Varela LM, Ip MM. Tumor necrosis factor-α: a multifunctional regulator of mammary gland development. Endocrinology 1996;137:4915-24.
11. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
12. Breit S, Nees M, Schaefer U, et al. Impact of pre-analytical handling on bone marrow mRNA gene expression. Br J Haematol 2004;126:231-43.